REED - Revista Española de Enfermedades Digestivas

New issue alert	Contact
Submit a manuscript	Follow REEDigestivas_
Versión en español

Year 2019 / Volume 111 / Number 4
Original

Comparative study of overweight and obese patients with nonalcoholic fatty liver disease

256-263

DOI: 10.17235/reed.2019.5926/2018

Rocío Aller, Beatriz Burgueño Gomez, Rebeca Sigüenza, Conrado Fernández-Rodríguez, Natalia Fernández, Beatriz Antolín, Miguel Durà, María Pina, Sara Lorenzo, Concepción García, Daniel de Luis Román,

Abstract

Background and aims: non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder in the western world. Although NAFLD prevalence is higher in patients with a BMI > 25 kg /m2, it is unclear if there are differences between overweight and obese patients. The associated biochemical, dietary and genetic parameters were compared between overweight and obese patients with NAFLD. Methods: patients with biopsy-proven NAFLD (n = 203) were enrolled in a cross-sectional study. The MEDAS questionnaire was used to assess adherence to the Mediterranean diet. Biochemical, anthropometrical parameters and the I148M variant (rs738409) of the PNPLA3 gene and rs180069 of the TNF-α gene were evaluated. Results: overweight patients had higher serum adiponectin levels (22.5 ± 21.9 vs 11.2 ± 18.1 ng/ml; p < 0.05) and lower resistin (3.3 ± 1.7 vs 8.1 ± 8 ng/ml; p < 0.001) and leptin concentrations (22.9 ± 21.9 vs 55.8 ± 45 ng/ml; p < 0.001) than obese patients. Non-alcoholic steatohepatitis (NASH) was more frequent in the obese group (59.3% vs 41.3%; p = 0.02). The multivariate analysis showed adherence to the Mediterranean diet to be an independent protective factor for NASH and liver fibrosis in overweight patients (OR 0.7, 95% CI 0.5-0.8). Conclusions: NASH was more prevalent in obese patients than in overweight subjects. HOMA-IR and adherence to the Mediterranean diet provided protection against fibrosis in overweight patients. Adherence to the Mediterranean diet was the only independent factor associated with NASH in these patients.

New comment

Comments

No comments for this article

References

1. Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism: clinical and experimental. 2016;65(8):1017-25.

DOI: 10.1016/j.metabol.2016.01.012

2. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (Baltimore, Md). 2006;44(4):865-73.

DOI: 10.1002/hep.21327

3. Zhang S, Du T, Li M, Jia J, Lu H, Lin X, et al. Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects. Medicine. 2017;96(22):e7041.

DOI: 10.1097/MD.0000000000007041

4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-9.

DOI: 10.1016/S0016-5085(99)70506-8

5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-52.

DOI: 10.1161/CIRCULATIONAHA.105.169404

6. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (Baltimore, Md). 2004;40(6):1387-95.

DOI: 10.1002/hep.20466

7. Kim D, Kim WR. Nonobese Fatty Liver Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2017;15(4):474-85.

DOI: 10.1016/j.cgh.2016.08.028

8. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592-609.

DOI: 10.1053/j.gastro.2012.04.001

9. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. Journal of hepatology. 2010;53(2):372-84.

DOI: 10.1016/j.jhep.2010.04.008

10. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Archives of internal medicine. 2008;168(15):1617-24.

DOI: 10.1001/archinte.168.15.1617

11. Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Current pharmaceutical design. 2013;19(29):5219-38.

DOI: 10.2174/13816128113199990381

12. Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver international : official journal of the International Association for the Study of the Liver. 2017;37 Suppl 1:85-9.

DOI: 10.1111/liv.13301

13. Duart Duart MJ, Arroyo CO, Moreno Frigols JL. Validation of a kinetic model for the reactions in RIA. Clinical chemistry and laboratory medicine. 2002;40(11):1161-7.

DOI: 10.1515/cclm.2002.203

14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9.

DOI: 10.1007/BF00280883

15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry. 1972;18(6):499-502.

16. Pfutzner A, Langenfeld M, Kunt T, Lobig M, Forst T. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clinical laboratory. 2003;49(11-12):571-6.

17. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clinical chemistry. 2004;50(9):1511-25.

DOI: 10.1373/clinchem.2004.032482

18. Suominen P. Evaluation of an enzyme immunometric assay to measure serum adiponectin concentrations. Clinical chemistry. 2004;50(1):219-21.

DOI: 10.1373/clinchem.2003.025833

19. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama. 2001;285(19):2486-97.

DOI: 10.1001/jama.285.19.2486

20. Leung JC, Loong TC, Wei JL, Wong GL, Chan AW, Choi PC, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology (Baltimore, Md). 2017;65(1):54-64.

DOI: 10.1002/hep.28697

21. Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World journal of gastrointestinal pathophysiology. 2017;8(2):11-26.

DOI: 10.4291/wjgp.v8.i2.11

22. Gatselis NK, Ntaios G, Makaritsis K, Dalekos GN. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clinical and experimental medicine. 2014;14(2):121-31.

DOI: 10.1007/s10238-012-0227-0

23. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (Baltimore, Md). 2002;36(2):403-9.

DOI: 10.1053/jhep.2002.34738

24. Stojsavljevic S, Gomercic Palcic M, Virovic Jukic L, Smircic Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World journal of gastroenterology. 2014;20(48):18070-91.

DOI: 10.3748/wjg.v20.i48.18070

25. Gil-Gomez A, Gomez-Sotelo AI, Ranchal I, Rojas A, Garcia-Valdecasas M, Munoz-Hernandez R, et al. Metformin modifies glutamine metabolism in an in vitro and in vivo model of hepatic encephalopathy. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 2018;110.

26. Hashiba M, Ono M, Hyogo H, Ikeda Y, Masuda K, Yoshioka R, et al. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PloS one. 2013;8(11):e76161.

DOI: 10.1371/journal.pone.0076161

27. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. Journal of hepatology. 2004;41(6):943-9.

DOI: 10.1016/j.jhep.2004.08.020

28. Sofi F, Casini A. Mediterranean diet and non-alcoholic fatty liver disease: new therapeutic option around the corner? World journal of gastroenterology. 2014;20(23):7339-46.

DOI: 10.3748/wjg.v20.i23.7339

29. Aller R, Izaola O, de la Fuente B, De Luis Roman DA. MEDITERRANEAN DIET IS ASSOCIATED WITH LIVER HISTOLOGY IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE. Nutricion hospitalaria. 2015;32(6):2518-24.

30. Tzima N, Pitsavos C, Panagiotakos DB, Chrysohoou C, Polychronopoulos E, Skoumas J, et al. Adherence to the Mediterranean diet moderates the association of aminotransferases with the prevalence of the metabolic syndrome; the ATTICA study. Nutrition & metabolism. 2009;6:30.

DOI: 10.1186/1743-7075-6-30

31. Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. Journal of hepatology. 2013;59(1):138-43.

DOI: 10.1016/j.jhep.2013.02.012

32. Kontogianni MD, Tileli N, Margariti A, Georgoulis M, Deutsch M, Tiniakos D, et al. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clinical nutrition (Edinburgh, Scotland). 2014;33(4):678-83.

DOI: 10.1016/j.clnu.2013.08.014

33. Shin KC, Chung JH, Lee KH. Effects of TNF-alpha and leptin on weight loss in patients with stable chronic obstructive pulmonary disease. The Korean journal of internal medicine. 2007;22(4):249-55.

DOI: 10.3904/kjim.2007.22.4.249

34. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology (Baltimore, Md). 2001;34(6):1158-63.

DOI: 10.1053/jhep.2001.29628

35. Morin CL, Schlaepfer IR, Eckel RH. Tumor necrosis factor-alpha eliminates binding of NF-Y and an octamer-binding protein to the lipoprotein lipase promoter in 3T3-L1 adipocytes. The Journal of clinical investigation. 1995;95(4):1684-9.

DOI: 10.1172/JCI117844

36. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 2002;122(2):274-80.

DOI: 10.1053/gast.2002.31065

1. Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism: clinical and experimental. 2016;65(8):1017-25.

DOI: 10.1016/j.metabol.2016.01.012

DOI: 10.1002/hep.21327

3. Zhang S, Du T, Li M, Jia J, Lu H, Lin X, et al. Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects. Medicine. 2017;96(22):e7041.

DOI: 10.1097/MD.0000000000007041

4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-9.

DOI: 10.1016/S0016-5085(99)70506-8

DOI: 10.1161/CIRCULATIONAHA.105.169404

6. Gomez de la Cuesta S, Aller de la Fuente R, Tafur Sanchez C, Izaola O, Garcia Sanchez C, Mora N, et al. Analytical, anthropometric and dietary factors associated with the development of fibrosis in patients with nonalcoholic fatty liver disease. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 2018;110(5):292-8.

7. Ampuero J, Gallego-Duran R, Romero-Gomez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 2015;107(1):10-6.

8. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (Baltimore, Md). 2004;40(6):1387-95.

DOI: 10.1002/hep.20466

9. Kim D, Kim WR. Nonobese Fatty Liver Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2017;15(4):474-85.

DOI: 10.1016/j.cgh.2016.08.028

10. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592-609.

DOI: 10.1053/j.gastro.2012.04.001

11. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. Journal of hepatology. 2010;53(2):372-84.

DOI: 10.1016/j.jhep.2010.04.008

12. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Archives of internal medicine. 2008;168(15):1617-24.

DOI: 10.1001/archinte.168.15.1617

13. Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Current pharmaceutical design. 2013;19(29):5219-38.

DOI: 10.2174/13816128113199990381

14. Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver international : official journal of the International Association for the Study of the Liver. 2017;37 Suppl 1:85-9.

DOI: 10.1111/liv.13301

15. Duart Duart MJ, Arroyo CO, Moreno Frigols JL. Validation of a kinetic model for the reactions in RIA. Clinical chemistry and laboratory medicine. 2002;40(11):1161-7.

16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry. 1972;18(6):499-502.

17. Pfutzner A, Langenfeld M, Kunt T, Lobig M, Forst T. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clinical laboratory. 2003;49(11-12):571-6.

18. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clinical chemistry. 2004;50(9):1511-25.

DOI: 10.1373/clinchem.2004.032482

19. Suominen P. Evaluation of an enzyme immunometric assay to measure serum adiponectin concentrations. Clinical chemistry. 2004;50(1):219-21.

DOI: 10.1373/clinchem.2003.025833

20. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama. 2001;285(19):2486-97.

DOI: 10.1001/jama.285.19.2486

21. Leung JC, Loong TC, Wei JL, Wong GL, Chan AW, Choi PC, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology (Baltimore, Md). 2017;65(1):54-64.

DOI: 10.1002/hep.28697

22. Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World journal of gastrointestinal pathophysiology. 2017;8(2):11-26.

DOI: 10.4291/wjgp.v8.i2.11

23. Gatselis NK, Ntaios G, Makaritsis K, Dalekos GN. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clinical and experimental medicine. 2014;14(2):121-31.

DOI: 10.1007/s10238-012-0227-0

24. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (Baltimore, Md). 2002;36(2):403-9.

DOI: 10.1053/jhep.2002.34738

25. Stojsavljevic S, Gomercic Palcic M, Virovic Jukic L, Smircic Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World journal of gastroenterology. 2014;20(48):18070-91.

DOI: 10.3748/wjg.v20.i48.18070

DOI: 10.1371/journal.pone.0076161

27. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. Journal of hepatology. 2004;41(6):943-9.

DOI: 10.1016/j.jhep.2004.08.020

28. Sofi F, Casini A. Mediterranean diet and non-alcoholic fatty liver disease: new therapeutic option around the corner? World journal of gastroenterology. 2014;20(23):7339-46.

DOI: 10.3748/wjg.v20.i23.7339

DOI: 10.1186/1743-7075-6-30

31. Kontogianni MD, Tileli N, Margariti A, Georgoulis M, Deutsch M, Tiniakos D, et al. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clinical nutrition (Edinburgh, Scotland). 2014;33(4):678-83.

DOI: 10.1016/j.clnu.2013.08.014

32. Shin KC, Chung JH, Lee KH. Effects of TNF-alpha and leptin on weight loss in patients with stable chronic obstructive pulmonary disease. The Korean journal of internal medicine. 2007;22(4):249-55.

DOI: 10.3904/kjim.2007.22.4.249

33. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology (Baltimore, Md). 2001;34(6):1158-63.

DOI: 10.1053/jhep.2001.29628

34. Morin CL, Schlaepfer IR, Eckel RH. Tumor necrosis factor-alpha eliminates binding of NF-Y and an octamer-binding protein to the lipoprotein lipase promoter in 3T3-L1 adipocytes. The Journal of clinical investigation. 1995;95(4):1684-9.

DOI: 10.1172/JCI117844

35. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 2002;122(2):274-80.

DOI: 10.1053/gast.2002.31065

1. Fazel Y, Koenig AB, Sayiner M, et al. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism: clinical and experimental. 2016;65(8):1017-25.

DOI: 10.1016/j.metabol.2016.01.012

2. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (Baltimore, Md). 2006;44(4):865-73.

DOI: 10.1002/hep.21327

3. Zhang S, Du T, Li M, et al. Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects. Medicine. 2017;96(22):e7041.

DOI: 10.1097/MD.0000000000007041

4. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-9.

DOI: 10.1016/S0016-5085(99)70506-8

5. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-52.

DOI: 10.1161/CIRCULATIONAHA.105.169404

6. Gomez de la Cuesta S, Aller de la Fuente R, Tafur Sanchez C, et al. Analytical, anthropometric and dietary factors associated with the development of fibrosis in patients with nonalcoholic fatty liver disease. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 2018;110(5):292-8.

DOI: 10.17235/reed.2018.5118/2017

8. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (Baltimore, Md). 2004;40(6):1387-95.

DOI: 10.1002/hep.20466

9. Kim D, Kim WR. Nonobese Fatty Liver Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2017;15(4):474-85.

DOI: 10.1016/j.cgh.2016.08.028

10. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592-609.

DOI: 10.1053/j.gastro.2012.04.001

11. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. Journal of hepatology. 2010;53(2):372-84.

DOI: 10.1016/j.jhep.2010.04.008

12. Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Archives of internal medicine. 2008;168(15):1617-24.

DOI: 10.1001/archinte.168.15.1617

13. Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Current pharmaceutical design. 2013;19(29):5219-38.

DOI: 10.2174/13816128113199990381

14. Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver international : official journal of the International Association for the Study of the Liver. 2017;37 Suppl 1:85-9.

DOI: 10.1111/liv.13301

15. Duart Duart MJ, Arroyo CO, Moreno Frigols JL. Validation of a kinetic model for the reactions in RIA. Clinical chemistry and laboratory medicine. 2002;40(11):1161-7.

DOI: 10.1515/cclm.2002.203

17. Pfutzner A, Langenfeld M, Kunt T,et al. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clinical laboratory. 2003;49(11-12):571-6.

DOI: 10.1373/clinchem.2004.032482

19. Suominen P. Evaluation of an enzyme immunometric assay to measure serum adiponectin concentrations. Clinical chemistry. 2004;50(1):219-21.

DOI: 10.1373/clinchem.2003.025833

DOI: 10.1001/jama.285.19.2486

21. Leung JC, Loong TC, Wei JL, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology (Baltimore, Md). 2017;65(1):54-64.

DOI: 10.1002/hep.28697

22. Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World journal of gastrointestinal pathophysiology. 2017;8(2):11-26.

DOI: 10.4291/wjgp.v8.i2.11

23. Gatselis NK, Ntaios G, Makaritsis K, et al . Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clinical and experimental medicine. 2014;14(2):121-31.

DOI: 10.1007/s10238-012-0227-0

24. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (Baltimore, Md). 2002;36(2):403-9.

DOI: 10.1053/jhep.2002.34738

25. Stojsavljevic S, Gomercic Palcic M, Virovic Jukic L, et al. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World journal of gastroenterology. 2014;20(48):18070-91.

DOI: 10.3748/wjg.v20.i48.18070

26. Hashiba M, Ono M, Hyogo H, et al. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PloS one. 2013;8(11):e76161.

DOI: 10.1371/journal.pone.0076161

27. Angulo P, Alba LM, Petrovic LM, et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. Journal of hepatology. 2004;41(6):943-9.

DOI: 10.1016/j.jhep.2004.08.020

28. Garcia-Monzon C, Vargas-Castrillon J, Porrero JL, et al. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones. Liver international : official journal of the International Association for the Study of the Liver. 2015;35(8):1983-91.

DOI: 10.1111/liv.12813

29. Sofi F, Casini A. Mediterranean diet and non-alcoholic fatty liver disease: new therapeutic option around the corner? World journal of gastroenterology. 2014;20(23):7339-46.

DOI: 10.3748/wjg.v20.i23.7339

30. Aller R, Izaola O, de la Fuente B, et al. Mediterranean diet is associated with liver histology in patients with non alcoholic fatty liver disease. Nutricion hospitalaria. 2015;32(6):2518-24.

31. Tzima N, Pitsavos C, Panagiotakos DB, et al. Adherence to the Mediterranean diet moderates the association of aminotransferases with the prevalence of the metabolic syndrome; the ATTICA study. Nutrition & metabolism. 2009;6:30.

DOI: 10.1186/1743-7075-6-30

32. Kontogianni MD, Tileli N, Margariti A, et al. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clinical nutrition (Edinburgh, Scotland). 2014;33(4):678-83.

DOI: 10.1016/j.clnu.2013.08.014

33. Anstee QM, Day CP. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. Seminars in liver disease. 2015;35(3):270-90.

DOI: 10.1055/s-0035-1562947

34. De Luis DA, Aller R, Izaola O, et al . Association of the TNF-alpha -308 G/A polymorphisms with metabolic responses secondary to a high protein/low carbohydrate versus a standard hypocaloric diet. Nutricion hospitalaria. 2016;33(3):267

35. Shin KC, Chung JH, Lee KH. Effects of TNF-alpha and leptin on weight loss in patients with stable chronic obstructive pulmonary disease. The Korean journal of internal medicine. 2007;22(4):249-55.

DOI: 10.3904/kjim.2007.22.4.249

36. Crespo J, Cayon A, Fernandez-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology (Baltimore, Md). 2001;34(6):1158-63.

DOI: 10.1053/jhep.2001.29628

37. Morin CL, Schlaepfer IR, Eckel RH. Tumor necrosis factor-alpha eliminates binding of NF-Y and an octamer-binding protein to the lipoprotein lipase promoter in 3T3-L1 adipocytes. The Journal of clinical investigation. 1995;95(4):1684-9.

DOI: 10.1172/JCI117844

38. Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 2002;122(2):274-80.

DOI: 10.1053/gast.2002.31065

Original

Prognostic value of liver stiffness in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis

DOI: 10.17235/reed.2024.10353/2024

Review

Association between platelet indices and non-alcoholic fatty liver disease: a systematic review and meta-analysis

DOI: 10.17235/reed.2022.9142/2022

Original

Prevalence of non-alcoholic fatty liver disease in pediatric mental disorder inpatients: a tertiary mental health referral hospital study

DOI: 10.17235/reed.2022.8986/2022

Original

Probiotics and non-alcoholic fatty liver disease in children and adolescents: a systematic review

DOI: 10.17235/reed.2022.8796/2022

Original

Liver stiffness accuracy by magnetic resonance elastography in histologically proven non-alcoholic fatty liver disease patients: a Spanish cohort

DOI: 10.17235/reed.2022.8777/2022

Editorial

Non-invasive liver fibrosis tests in non-alcoholic fatty liver disease

DOI: 10.17235/reed.2022.8718/2022

Editorial

Looking for a new name for non-alcoholic fatty liver disease in Spanish: esteatosis hepática metabólica (EHmet)

DOI: 10.17235/reed.2021.7862/2021

Review

Metabolic syndrome, non-alcoholic fatty liver disease and hepatocarcinoma

DOI: 10.17235/reed.2020.6640/2019

Original

The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials

DOI: 10.17235/reed.2020.6392/2019

Editorial

Characterizing specific subgroups in patients with NAFLD: overweight vs obese phenotype

DOI: 10.17235/reed.2019.6269/2019

Original

Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria

DOI: 10.17235/reed.2019.6088/2018

Original

An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity

DOI: 10.17235/reed.2019.6068/2018

Original

Risk factors differentially associated with non-alcoholic fatty liver disease in males and females with metabolic syndrome

DOI: 10.17235/reed.2019.6031/2018

Original

Association between thymosin beta4 and non-alcoholic fatty liver disease

DOI: 10.17235/reed.2019.5927/2018

Original

Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease

DOI: 10.17235/reed.2018.5602/2018

Case Report

Nonalcoholic steatohepatitis and hepatic adenomatosis: casual or causal relationship?

DOI: 10.17235/reed.2017.4981/2017

Original

Insulin resistance and the metabolic syndrome are related to the severity of steatosis in the pediatric population with obesity

DOI: 10.17235/reed.2017.4898/2017

Original

Characterization of liver changes in ZSF1 rats, an animal model of metabolic syndrome

DOI: 10.17235/reed.2017.4575/2016

Citation tools

Aller R, Burgueño Gomez B, Sigüenza R, Fernández-Rodríguez C, Fernández N, Antolín B, et all. Comparative study of overweight and obese patients with nonalcoholic fatty liver disease . 5926/2018

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics

This article has received 1400 visits.
This article has been downloaded 460 times.

Statistics from Dimensions

Statistics from Plum Analytics

Publication history

Received: 17/09/2018

Accepted: 29/11/2018

Online First: 11/02/2019

Published: 04/04/2019

Article revision time: 60 days

Article Online First time: 147 days

Article editing time: 199 days

This article has been rated by 2 readers.

Reader rating:

Valora este artículo:

Submission and tracking of manuscripts

Instructions to authors

Submission and tracking

Home

Articles

Current issues

Previous issues

Cookie	Purpose	Expiration	Cookie type
ASP.NET_SessionId	Makes it possible to control traffic from the server to multiple users at the same time, identification and access as a user.	Logout / End of project	Session
cookiesDirective	Makes it possible to remember cookie settings.	Logout / End of project	Session
vercookies	Makes it possible to display the notice on the use of cookies.	Logout / End of project	Session

Download to a citation manager

Statistics from Dimensions

Statistics from Plum Analytics

Submission and tracking of manuscripts

Receive the digital monthly newsletter of the REED

In accordance with current legislation, this publication is only for health care professionals.